Major Study Led by Henry Ford Health System Reveals Hydroxychloroquine Cuts COVID-19 Death Rate

Major Study Led by Henry Ford Health System Reveals Hydroxychloroquine Cuts COVID-19 Death Rate

A new study led by Henry Ford Health System reveals that hydroxychloroquine cut the death rate significantly in patients hospitalized with COVID-19—and without heart-related side effects. The large-scale retrospective analysis of 2,541 patients was recently published in the International Journal of Infectious Diseases. 

This study does counter to a number of claims and trends of late where hydroxychloroquine fell out of favor, perhaps as TrialSite News has reported, due to various mishaps and perhaps some politics.

The Study

This retrospective study involved the analysis of patients hospitalized from March 10 to May 2, 2020 across the system’s six hospitals. The investigators found that 13% of those treated with hydroxychloroquine alone died compared to 26.4% not treated with hydroxychloroquine. None of the patients, reports the Henry Ford Health System, experienced serious heart abnormalities. However, patients were monitored for a heart condition routinely pointed to as a reason to avoid the drug as a COVID-19 treatment. 

The Details

Patients treated with hydroxychloroquine at Henry Ford met specific protocol criteria as outlined by the hospital system’s Division ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee